Understanding eGFR and uPCR is vital for managing IgA nephropathy to predict kidney health, guide treatment, and work effectively with healthcare providers in slowing disease progression.

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

In unadjusted analysis, rates of DKA among individuals with an eGFR between 30 and 90 mL/min/1.73 m 2 showed no statistical ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...